Production (Stage)
Tiziana Life Sciences Ltd
TLSA
$1.58
$0.2115.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 48.54% | 48.54% | -27.27% | -27.27% | -2.51% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.05% | -0.05% | -25.14% | -25.14% | -7.75% |
| Operating Income | 0.05% | 0.05% | 25.14% | 25.14% | 7.75% |
| Income Before Tax | -1.63% | -1.63% | 7.39% | 7.39% | 20.76% |
| Income Tax Expenses | -446.77% | -446.77% | -- | -- | -- |
| Earnings from Continuing Operations | 20.55% | 20.55% | 45.99% | 45.99% | 16.63% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.55% | 20.55% | 45.99% | 45.99% | 16.63% |
| EBIT | 0.05% | 0.05% | 25.14% | 25.14% | 7.75% |
| EBITDA | 0.06% | 0.06% | 25.20% | 25.20% | 7.78% |
| EPS Basic | 26.02% | 26.02% | 46.32% | 46.32% | 14.67% |
| Normalized Basic EPS | 2.02% | 2.02% | 27.07% | 27.07% | 16.78% |
| EPS Diluted | 26.02% | 26.02% | 46.32% | 46.32% | 14.67% |
| Normalized Diluted EPS | 2.02% | 2.02% | 27.07% | 27.07% | 16.78% |
| Average Basic Shares Outstanding | 7.38% | 7.38% | 0.81% | 0.81% | -2.33% |
| Average Diluted Shares Outstanding | 7.38% | 7.38% | 0.81% | 0.81% | -2.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |